Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: Implications for treatment of immune thrombocytopenic purpura

Blood

Volumn 101, Issue 2, 2003, Pages 621-623

  Kuwana, Masataka ^a   Kawakami, Yutaka ^a   Ikeda, Yasuo ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GAMMA INTERFERON; INTERLEUKIN 10;

ANTIBODY PRODUCTION; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DRUG SCREENING; HELPER CELL; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; T LYMPHOCYTE;

EID: 0037438507     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-07-2157     Document Type: Article

References (25)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346:995-1008.
2. Karpatkin S. Autoimmune (idiopathic) thrombocytopenic purpura. Lancet. 1997;349:1531-1536.
3. Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb/IIIa in immune thrombocytopenic purpura: role in production of anti-platelet autoantibody. J Clin Invest. 1998;102:1393-1402.
4. Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb/IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001;98:130-139.
5. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168:3675-3682.
6. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol. 1996;16:59-108.
7. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
8. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995;154:1470-1480.
9. Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest. 1999;103:281-290.
10. Im SH, Barchan D, Maiti PK, Fuchs S, Souroujon MC. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol. 2001;166:6893-6898.
11. Datta SK, Kalled SL. CD40-CD40 ligand interaction in autoimmune disease. Arthritis Rheum. 1997;40:1735-1745.
12. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5:686-693.
13. Davis JC Jr, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:95-101.
14. Kenyon NS, Chtzipetrou M, Masetti M, et al. Long-term survival and function of intrahepaiic islet allografts in rhesus monkeys with humanized anti-CD154. Proc Natl Acad Sci U S A. 1999;96:8132-8137.
15. Kuwana M, Medsger TA Jr, Wright TM. T-B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol. 1995;155:2703-2714.
16. + T cell anergy by peripheral blood DC2 precursors. Eur J Immunol. 2001;31:2547-2557.
17. Brams P, Black A, Padlan EA, et al. A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int Immunopharmacol. 2001;1:277-294.
18. Kuwana M, Medsger TA Jr, Wright TM. Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive cells. J Immunol. 2000;164:6138-6146.
19. + T cell clones to β2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood. 2001;98:1889-1896.
20. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med. 1996;184:1-8.
21. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737-742.
22. Homann D, Jahreis A, Wilfe T, et al. CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity. 2002;16:403-415.
23. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med. 2000;6:114.
24. Henn V, Steinbach S, Büchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047-1054.
25. 3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.